151 related articles for article (PubMed ID: 36576110)
21. MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.
Caner V; Sen Turk N; Baris IC; Cetin GO; Tepeli E; Hacioglu S; Sari I; Zencir S; Dogu MH; Bagci G; Keskin A
Genet Test Mol Biomarkers; 2015 Jul; 19(7):372-8. PubMed ID: 25978699
[TBL] [Abstract][Full Text] [Related]
22. Recurrent Mutations in Refractory/Relapsed Diffuse Large B-Cell Lymphoma by Targeted Gene Sequencing.
Sharma A; Das A; Bal A; Srinivasan R; Malhotra P; Prakash G; Kumar R
Cytogenet Genome Res; 2023; 163(5-6):279-289. PubMed ID: 38071955
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma.
Ebid OAEH; Ezz El Arab LR; Saad AS; Ezz El Din M; Mostafa N; Swellam M
Ann Hematol; 2023 Dec; 102(12):3477-3488. PubMed ID: 37658234
[TBL] [Abstract][Full Text] [Related]
24. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
[TBL] [Abstract][Full Text] [Related]
25. [Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas].
Huo YJ; Zhang MC; Shi Q; Qin W; Shi ZY; Wang L; Cheng S; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):55-61. PubMed ID: 36987724
[No Abstract] [Full Text] [Related]
26. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
[TBL] [Abstract][Full Text] [Related]
27. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.
Oishi N; Kondo T; Nakazawa T; Mochizuki K; Tanioka F; Oyama T; Yamamoto T; Iizuka J; Tanabe K; Shibata N; Kirito K; Katoh R
Pathol Int; 2015 Oct; 65(10):528-35. PubMed ID: 26388135
[TBL] [Abstract][Full Text] [Related]
28. Next-Generation Sequencing Highlights of Diffuse Large B-cell Lymphoma in a Tertiary Care Hospital in North India.
Mamgain G; Naithani M; Patra P; Mamgain M; Morang S; Nayak J; Kumar K; Singh S; Bakliwal A; Rajoreya A; Vaniyath S; Chattopadhyay D; Chetia R; Gupta A; Dhingra G; Sundriyal D; Nath UK
Cureus; 2022 Aug; 14(8):e28241. PubMed ID: 36158348
[TBL] [Abstract][Full Text] [Related]
29. Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez Pereña A; Marcos Gonzalez S; Teran-Villagra N; Azueta A; Batlle A; Gonzalez de Villambrosia S; Revert Arce J; Montes-Moreno S
Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):e68-e71. PubMed ID: 29629945
[TBL] [Abstract][Full Text] [Related]
30. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
[TBL] [Abstract][Full Text] [Related]
31. Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.
Dubois S; Viailly PJ; Mareschal S; Bohers E; Bertrand P; Ruminy P; Maingonnat C; Jais JP; Peyrouze P; Figeac M; Molina TJ; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Brière J; Petrella T; Canioni D; Fabiani B; Coiffier B; Delarue R; Peyrade F; Bosly A; André M; Ketterer N; Salles G; Tilly H; Leroy K; Jardin F
Clin Cancer Res; 2016 Jun; 22(12):2919-28. PubMed ID: 26819451
[TBL] [Abstract][Full Text] [Related]
32. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.
Dobashi A
J Clin Exp Hematop; 2016; 56(2):71-78. PubMed ID: 27980305
[TBL] [Abstract][Full Text] [Related]
33. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
34. Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.
Kim E; Jiang Y; Xu T; Bazeos A; Knapp A; Bolen CR; Humphrey K; Nielsen TG; Penuel E; Paulson JN
BMC Cancer; 2022 Mar; 22(1):231. PubMed ID: 35236331
[TBL] [Abstract][Full Text] [Related]
35. CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
Kim Y; Ju H; Kim DH; Yoo HY; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR.
Niu J; Ma Z; Nuerlan A; Li S; Cui W; Gao H; Abulajiang G; Zhang W; Li X
Mol Med Rep; 2020 Aug; 22(2):1243-1256. PubMed ID: 32468019
[TBL] [Abstract][Full Text] [Related]
37. Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.
Bohers E; Mareschal S; Bertrand P; Viailly PJ; Dubois S; Maingonnat C; Ruminy P; Tilly H; Jardin F
Leuk Lymphoma; 2015 May; 56(5):1213-22. PubMed ID: 25130477
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.
Lee JH; Jeong H; Choi JW; Oh H; Kim YS
Sci Rep; 2017 May; 7(1):1785. PubMed ID: 28496180
[TBL] [Abstract][Full Text] [Related]
39. Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?
Boiza-Sánchez M; Manso R; Balagué O; Chamizo C; Askari E; Salgado RN; Blas-López C; Aguirregoicoa-García E; Menárguez J; Santonja C; Adrados M; Limeres-González MÁ; Piris MÁ; Rodríguez-Pinilla SM
PLoS One; 2020; 15(11):e0241634. PubMed ID: 33180881
[TBL] [Abstract][Full Text] [Related]
40. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
Cao XX; Li J; Cai H; Zhang W; Duan MH; Zhou DB
Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
